Table 1 Clinicopathologic features of the ten patients with ovarian immature teratomas studied by whole-exome sequencing.

From: Multiregion exome sequencing of ovarian immature teratomas reveals 2N near-diploid genomes, paucity of somatic mutations, and extensive allelic imbalances shared across mature, immature, and disseminated components

Patient	Age at initial resection	Bilateral ovarian disease	Pathologic diagnosis	Summary of clinical treatment	Status at last follow-up	Length of follow-up
a	16 years	Synchronous	L ovary (26 cm): immature teratoma (grade 3)^a with microscopic foci of yolk sac tumor and embryonal carcinoma	Resections of synchronous bilateral ovarian masses and debulking of disseminated peritoneal disease, chemotherapy with bleomycin + etoposide + cisplatin × 4 cycles, subsequent resections of residual disease at 1.1 and 2.3 years after initial resection	Alive with stable disease	5.5 years
			R ovary (12 cm): predominantly mature teratoma with microscopic foci of immature teratoma (grade 1)
			Peritoneum: disseminated mature^a and immature teratoma^a, gliomatosis peritonei, yolk sac tumor^a
b	19 years	Synchronous	L ovary (22 cm): immature teratoma (grade 3)^a	Resections of synchronous bilateral ovarian masses and debulking of disseminated peritoneal disease, chemotherapy with bleomycin + etoposide + cisplatin × 4 cycles, subsequent resection of residual disease at 0.8 years after initial resection	Alive without evidence of disease recurrence/progression	5.4 years
			R ovary (9 cm): mature teratoma^a only
			peritoneum: disseminated mature^a and immature teratoma^a, gliomatosis peritonei^a
			peritoneal lymph nodes: metastatic mature teratoma
c	18 years	No	R ovary (18 cm): immature teratoma (grade 3)^a	Resection of unilateral ovarian mass	Alive without evidence of disease recurrence/progression	5.9 years
			L ovary: no disease
			Peritoneum: no disease
d	14 years	No	L ovary (18 cm): immature teratoma (grade 2)^a	Resection of unilateral ovarian mass and debulking of disseminated peritoneal disease, subsequent PET/CT showing widespread bulky lymphadenopathy, excision of supraclavicular lymph node at 0.6 years after initial resection, chemotherapy with vincristine + doxorubicin + cyclophosphamide + ifosfamide + etoposide, subsequent resection of residual disease at 1.0 years after initial resection, recurrent retroperitoneal disease resected at 1.5 years after initial resection plus intraoperative radiation therapy, chemotherapy with temozolomide × 12 cycles, cyberknife radiotherapy to left axillary recurrence at 2.0 years after initial diagnosis, PET/CT at 2.5 years after initial resection showing multifocal recurrence, chemotherapy with cyclophosphamide + topotecan × 19 cycles	Alive with stable disease	6.6 years
			R ovary: no disease
			Peritoneum: disseminated primitive neuroectodermal tumor^a, atypical gliomatosis peritonei^a
			Supraclavicular and axillary lymph nodes: metastatic primitive neuroectodermal tumor and atypical gliomatosis
e	29 years	No	R ovary (15 cm): immature teratoma (grade 3)^a	Resection of unilateral ovarian mass and debulking of disseminated peritoneal disease, chemotherapy with bleomycin + etoposide + cisplatin × 4 cycles, then chemotherapy with cisplatin + ifosfamide + taxol × 3 cycles	Alive without evidence of disease recurrence/progression	15.3 years
			L ovary: no disease
			Peritoneum: disseminated immature teratoma^a, gliomatosis peritonei^a
			Pelvic lymph nodes: metastatic mature teratoma
g	25 years	Metachronous	L ovary (14 cm): immature teratoma (grade 3)^a with microscopic foci of yolk sac tumor^a and embryonal carcinoma	Resection of unilateral ovarian mass, resection of contralateral ovarian mass at 4.8 years after initial resection, omentectomy at 4.9 years after initial resection, chemotherapy with bleomycin + etoposide + cisplatin × 4 cycles	Alive without evidence of disease recurrence/progression	2.4 years
			R ovary (4 cm): mature teratoma^a only
			Peritoneum: no disease
h	8 years	Metachronous	L ovary (17 cm): immature teratoma (grade 1)^a	Resection of unilateral ovarian mass, resection of contralateral ovarian mass and debulking of disseminated peritoneal disease at 9.0 years after initial resection	Alive without evidence of disease recurrence/progression	14.4 years
			R ovary (16 cm): immature teratoma (grade 1)^a
			Peritoneum: gliomatosis peritonei^a
i	10 years	No	L ovary (18 cm): immature teratoma (grade 2)^a	Resection of unilateral ovarian mass	No clinical follow-up	0 years
			R ovary: no disease
			Peritoneum: no disease
j	10 years	Metachronous	R ovary (12 cm): immature teratoma (grade 3)^a	Resection of unilateral ovarian mass, resection of contralateral ovarian mass and debulking of peritoneal nodules at 5.6 years after initial resection	Alive without evidence of disease recurrence/progression	13.5 years
			L ovary (7 cm): mature teratoma^a only
			Peritoneum: gliomatosis peritonei^a
k	23 years	No	R ovary (6 cm): immature teratoma (grade 2)^a	Resection of unilateral ovarian mass, chemotherapy with bleomycin + etoposide + cisplatin × 3 cycles, resection of residual ipsilateral ovarian mass and peritoneal nodule at 0.4 years after initial resection	Alive without evidence of disease recurrence/progression	10.5 years
			L ovary: no disease
			Peritoneum: disseminated immature teratoma^a

^aSamples studied by whole-exome sequencing

Back to article page

Table 1 Clinicopathologic features of the ten patients with ovarian immature teratomas studied by whole-exome sequencing.

Search

Quick links